Neurologist&Neuroimmunologist. Unraveling the complexities of Multiple Sclerosis at @unicampania & @Imperialcollege.
London, England
Joined February 2020
- Tweets315
- Following447
- Followers422
- Likes1.9K
Pinned Tweet
🧠 What if the genetic subtype associated with the worst MS outcome is not the one with the most chronic active lesions?
Very happy to share our new study, just published in Acta Neuropathologica:
link.springer.com/article/10…
Gianmarco Abbadessa retweeted
We didn't know the mechanism for why relapse occurs in multiple sclerosis.
@NatureMedicine today:
Reactivation of the Epstein-Barr virus and priming of the immune response
nature.com/articles/s41591-0…
The future of multiple sclerosis won’t be defined only by new therapies. It will be defined by smarter use of the therapies we already have.
Happy to share our paper just published on Neurology Neuroimmunology & Neuroinflammation: neurology.org/doi/10.1212/NX…
After S1PRM withdrawal, OFA vs OCR? 🤔🧠
In our multicenter real-world study, switching to OFA was linked to lower relapse activity, less EDSS/disability worsening, and lower MRI activity vs OCR 📉
Paper: link.springer.com/article/10…
Gianmarco Abbadessa retweeted
Congrats to @SetPointMed for this landmark study in @NatureMedicine that led to FDA approval for targeting the vagus nerve inflammatory reflex to treat rheumatoid arthritis. rdcu.be/eVUwr.
Gianmarco Abbadessa retweeted
Longitudinal proteomic profiling of cerebrospinal fluid in untreated multiple sclerosis defines evolving disease biology
nature.com/articles/s41467-0…
Gianmarco Abbadessa retweeted
Sul rigore concesso (giustamente) a #DiLorenzo, l'#Inter ci costruirà la stagione intera.
Prima ingiocabili, ora intoccabili.
I had the opportunity to present at the 55th SIN Neurology Congress a study on multi-omic data integration in MS: linking patient transcriptomics, human genetics (coloc + MR), and treatment response to map how current therapies work — and to highlight next-step targets.#neurology
8
473
🔬First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis 💥
🗞️Full article here: lnkd.in/d2F7RrRB
📢 Real-world comparison of lymphopenia profiles in S1P receptor modulators for MS
Ozanimod & Ponesimod → higher lymphocyte counts
Siponimod → more severe lymphopenia
Rare grade 4 cases with Ozanimod & Siponimod
🔗 link.springer.com/article/10…
#MS #Neurology #S1Pmodulators
🔬 New study out! We identified a 6-miRNA serum signature in #Neurofibromatosis Type 1 (NF1) using sncRNA-seq + qRT-PCR validation.
🧬 These miRNAs are linked to key cancer pathways and dysregulated across multiple cancers.
📖 Read here: sciencedirect.com/science/ar…
2
188
🔬 How to Find Your Place in Translational Research
🗓 June 21 | 🕚 11:00–12:30 | 📍 EAN 2025, Helsinki
Join us for a career session young neurologists & clinician-scientists: real talk, real tools to thrive in translational neurology.
🚨 Save the date!
#EAN2025 #Neurology
📣 Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple Sclerosis 🧬 👨🔬
Out now on Annals of Clinical and Translational Neurology 🧠 🗞️
onlinelibrary.wiley.com/doi/…
2
107
Excited to share our new paper in @ScienceTM 🔬
We show that Treg-derived miR-142-3p is transferred via extracellular vesicles to T cells, suppressing their activation—a novel mechanism of immune tolerance.🧫
Honoured to be part of this team!🌟
science.org/doi/10.1126/scit…
7
163
New episode of eanCast: Weekly Neurology 🎙️
I moderated a discussion with Prof Heinz Wiendl on immunology in rare CNS disorders like NMO, MOGAD, and autoimmune encephalitis. 🧠
Listen here: open.spotify.com/episode/6nQ…
#Neuroimmunology #eanCast #Neurology #CNSdisorders
Gianmarco Abbadessa retweeted
Harvard notified me today that this K99 grant is terminated.
I’m overjoyed to announce that my K99/R00 proposal has been funded by @NIHAging as of today!! I am very excited about the project which is a collaboration with @LehtinenLab to study the blood-CSF barrier with new analytical tools I’ve developed in the @GygiLab. Feeling grateful!!
Switching from fingolimod to siponimod in SPMS patients is safe and well-tolerated. 💊
Our latest study just published—check it out! 🌟
#MS #Neurology #SPMS #Siponimod #Fingolimod
jns-journal.com/article/S002…
In this prospective observational study of SPMS patients, we found that switching from fingolimod to siponimod is safe and well-tolerated over a 6-month period, with no increase in disease reactivation.
1
1
85
Gianmarco Abbadessa retweeted
How we "guessed" the Pope using network science: inside the cardinal network. A study by me, Beppe Soda and Alessandro Iorio. Article: unibocconi.it/en/news/networ… @Unibocconi
